Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | MAT2A | P31153 | 7/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601425 | 0.90 | MAT2A (0.36) | HRH4MAT2APARP15TNKS2PARP2 | |
| SCHEMBL23576693 | 0.84 | MAT2A (0.35) | HRH4MAT2APARP15TNKS2PARP2 | |
| SCHEMBL29909100 | 0.84 | MAT2A (0.35) | HRH4MAT2APARP15TNKS2PARP2 | |
| SCHEMBL23577196 | 0.84 | PDGFRB (0.38) | HRH4MAT2AKMT2APRMT5CYP1A2 | |
| SCHEMBL29909162 | 0.84 | PDGFRB (0.38) | HRH4MAT2AKMT2APRMT5CYP1A2 | |
| SCHEMBL29909169 | 0.83 | HRH4 (0.36) | HRH4MAT2APARP15TNKS2PARP2 | |
| SCHEMBL23576913 | 0.83 | HRH4 (0.36) | HRH4MAT2APARP15TNKS2PARP2 | |
| SCHEMBL23601712 | 0.83 | MAT2A (0.36) | HRH4MAT2APRMT5CYP1A2SMN1; SMN2 | |
| SCHEMBL23577499 | 0.82 | CSF1R (0.44) | HRH4MAT2APRMT5CYP1A2TP53 | |
| SCHEMBL30961036 | 0.82 | CSF1R (0.44) | HRH4MAT2APRMT5CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | HRH4 3793/4885MAT2A 1551/4885PARP15 1230/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | HRH4 3793/4885MAT2A 1551/4885PARP15 1230/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | HRH4 3793/4885MAT2A 1551/4885PARP15 1230/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | HRH4 3793/4885MAT2A 1551/4885PARP15 1230/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | HRH4 3793/4885MAT2A 1551/4885PARP15 1230/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | HRH4 3793/4885MAT2A 1551/4885PARP15 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.